Innate Pharma

AGM Information • Apr 28, 2015

OUTCOME OF ANNUAL GENERAL MEETING OF APRIL 27, 2015

Marseille, France, April 28, 2015

Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces that during its Annual General Meeting ("AGM") which took place on April 27, 2015, in Marseille, France : A number of 27,560,731 votes were expressed out of a total of 53,144,454 shares with voting rights, representing a quorum of 51.86%. Details of the votes are available on the Company's website, in the investors' room (http://www.innate-pharma.com/AGMdocuments).

During the meeting, Véronique Chabernaud was appointed as a new member of the Supervisory Board.

"We are very pleased that Ms. Véronique Chabernaud joins the Supervisory Board of Innate Pharma. Her comprehensive career in the pharmaceutical industry and her extensive knowledge of public health issues will be an asset to the Company", said Gilles Brisson, Chairman of the Supervisory Board of Innate Pharma. He added: "As we embark in a new stage of growth with the major partnership signed with AstraZeneca, Innate Pharma strengthens its governance with a new independent member, in the perspective of a sustainable development."

Véronique Chabernaud, aged 53, oncologist and ESSEC graduate, occupied for 20 years both national and international top-ranked positions in the pharmaceutical industry notably at Sanofi-Aventis. She was also consultant with companies in the innovative technology sector (Genomic Health, BioSystems International, MaunaKea Technologies, Ariana Pharma). She is also interested by the development of a global health approach.

To date, the Supervisory Board of Innate Pharma is composed of:

• Gilles Brisson, Chairman, Independent member;
• Irina Staatz-Granzer, Vice-Chairman, Independent member;
• Novo Nordisk A/S, represented by Karsten Munk Knudsen, Non-independent member;
• Patrick Langlois, Non-independent member;
• Philippe Pouletty, Independent member;
• Michael Caligiuri, Independent member;
• Véronique Chabernaud, Independent member;
• BPI Groupe, represented by Olivier Martinez, Observer.

The 2014 Activity and Responsibility Report and the 2014 Reference Document of the Company are available on its website.

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company discovering and developing first-in-class therapeutic antibodies for the treatment of cancer and inflammatory diseases.

Its innovative approach has translated into major alliances with leaders in the biopharmaceutical industry such as Bristol-Myers Squibb, AstraZeneca and Novo Nordisk A/S.

The Company has two clinical-stage programs in immuno-oncology, a new therapeutic field that is changing cancer treatment by enhancing the capability of the body's own immune cells to recognize and kill cancer cells. Innate Pharma's science also has potential in chronic inflammatory diseases.

Listed on Euronext-Paris, Innate Pharma is based in Marseille, France, and had 99 employees as at December 31, 2014.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code	FR0010331421
Ticker code	IPH

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website or on Innate Pharma's website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Innate Pharma ATCG Press Laure-Hélène Mercier Director, Investor Relations Marie Puvieux: +33 (0)6 10 54 36 72 Judith Aziza: +33 (0)6 70 07 77 51 Tel.: +33 (0)4 30 30 30 87 investors@innate-pharma.com presse@atcg-partners.com